Arbutus Biopharma Corporation (FRA:I9DN)
Germany
· Delayed Price · Currency is EUR 3.708
+0.198 (5.64%)
At close: Dec 4, 2025
Arbutus Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 22.41 | 36.33 | 26.29 | 30.78 | 109.28 | 52.25 | Upgrade
|
| Short-Term Investments | 71.29 | 86.29 | 99.72 | 116.14 | 46.04 | 71.02 | Upgrade
|
| Cash & Short-Term Investments | 93.7 | 122.62 | 126 | 146.91 | 155.32 | 123.27 | Upgrade
|
| Cash Growth | -26.68% | -2.68% | -14.23% | -5.41% | 26.00% | 35.71% | Upgrade
|
| Accounts Receivable | 0.91 | 2.41 | 1.78 | 1.35 | 0.9 | 1.31 | Upgrade
|
| Other Receivables | 0.3 | 0.3 | 0.6 | - | - | - | Upgrade
|
| Receivables | 1.21 | 2.71 | 2.38 | 1.35 | 0.9 | 1.31 | Upgrade
|
| Prepaid Expenses | 2.54 | 1.98 | 3.65 | 2.87 | 4.45 | 3.12 | Upgrade
|
| Total Current Assets | 97.44 | 127.32 | 132.03 | 151.14 | 160.66 | 127.7 | Upgrade
|
| Property, Plant & Equipment | 0.14 | 4.36 | 6.09 | 6.81 | 8.08 | 9.33 | Upgrade
|
| Long-Term Investments | - | - | 6.28 | 37.36 | 35.69 | - | Upgrade
|
| Other Long-Term Assets | 0.13 | 0.03 | - | 0.1 | 0.06 | 0.04 | Upgrade
|
| Total Assets | 97.71 | 131.71 | 144.4 | 195.42 | 204.49 | 137.08 | Upgrade
|
| Accounts Payable | 1.01 | 2.32 | 3.22 | 3.52 | 3.17 | 2.99 | Upgrade
|
| Accrued Expenses | 2.88 | 5.25 | 7.05 | 12.51 | 7.66 | 6.16 | Upgrade
|
| Current Portion of Leases | 0.53 | 0.48 | 0.43 | 0.37 | 0.38 | 0.39 | Upgrade
|
| Current Unearned Revenue | - | 7.57 | 11.79 | 16.46 | - | - | Upgrade
|
| Other Current Liabilities | 0.76 | - | - | - | - | - | Upgrade
|
| Total Current Liabilities | 5.18 | 15.62 | 22.49 | 32.86 | 11.22 | 9.54 | Upgrade
|
| Long-Term Debt | 3.68 | 4.83 | 6.95 | 10.37 | 16.3 | 19.55 | Upgrade
|
| Long-Term Leases | 0.39 | 0.81 | 1.34 | 1.82 | 2.23 | 2.59 | Upgrade
|
| Long-Term Unearned Revenue | - | 2.86 | - | 6 | - | - | Upgrade
|
| Other Long-Term Liabilities | 11.05 | 10.23 | 7.6 | 7.53 | 5.3 | 3.43 | Upgrade
|
| Total Liabilities | 20.31 | 34.34 | 38.38 | 58.57 | 35.05 | 35.11 | Upgrade
|
| Common Stock | 1,419 | 1,410 | 1,350 | 1,319 | 1,287 | 985.94 | Upgrade
|
| Additional Paid-In Capital | 83.29 | 82.05 | 81.27 | 72.41 | 65.49 | 60.75 | Upgrade
|
| Retained Earnings | -1,376 | -1,347 | -1,277 | -1,204 | -1,134 | -1,046 | Upgrade
|
| Comprehensive Income & Other | -48.13 | -48.14 | -48.42 | -50.49 | -48.34 | -48.17 | Upgrade
|
| Total Common Equity | 77.4 | 97.37 | 106.02 | 136.85 | 169.44 | -47.44 | Upgrade
|
| Shareholders' Equity | 77.4 | 97.37 | 106.02 | 136.85 | 169.44 | 101.97 | Upgrade
|
| Total Liabilities & Equity | 97.71 | 131.71 | 144.4 | 195.42 | 204.49 | 137.08 | Upgrade
|
| Total Debt | 4.61 | 6.12 | 8.72 | 12.55 | 18.91 | 22.54 | Upgrade
|
| Net Cash (Debt) | 89.1 | 116.51 | 123.57 | 171.72 | 172.1 | 100.73 | Upgrade
|
| Net Cash Growth | -28.15% | -5.71% | -28.04% | -0.22% | 70.85% | 47.09% | Upgrade
|
| Net Cash Per Share | 0.47 | 0.63 | 0.74 | 1.14 | 1.62 | 1.33 | Upgrade
|
| Filing Date Shares Outstanding | 192.32 | 191.48 | 179.49 | 162.57 | 148.64 | 95.58 | Upgrade
|
| Total Common Shares Outstanding | 191.95 | 189.96 | 169.87 | 157.46 | 144.99 | 89.68 | Upgrade
|
| Working Capital | 92.26 | 111.7 | 109.54 | 118.28 | 149.44 | 118.16 | Upgrade
|
| Book Value Per Share | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 | -0.53 | Upgrade
|
| Tangible Book Value | 77.4 | 97.37 | 106.02 | 136.85 | 169.44 | -47.44 | Upgrade
|
| Tangible Book Value Per Share | 0.40 | 0.51 | 0.62 | 0.87 | 1.17 | -0.53 | Upgrade
|
| Machinery | - | 7.72 | 7.98 | 7.28 | 6.79 | 5.99 | Upgrade
|
| Leasehold Improvements | - | 8.59 | 8.59 | 8.59 | 8.56 | 8.56 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.